1Wallukat G, Fu ML, Maggnusson Y, et al. Agonistic effects of anti-peptide autibodies and autoantibodies directed against adrenergic and cholinergic rcceptor:absence of desensitization. Blood Pressure, 1996,5(Suppl 3):31-36.
2Podlowski S, Luther HP, Morwinski R, et al. Agonistic anti-β1- adrenergic rcceptor autoantibodies from cardiomyopathy patients reduce the β1- adrenergic rcceptor expression in neonatal rat cardiomyocytes. Circulation,1998,98:2470-2476.
3Luther HP, Homuth V, Wallukat G, et al. α1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension,1997,29:678-682.
4Nakajima T, Ma J, Zida H, et al. Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cell. Jpn Heart J, 2003,44:963-978.
5Yao A, Kohmoto O, Oyama T, et al. Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca2+] I in ventricular myocytes compared with those of timolol and atenolol. Circ J,2003,67:83-90.
6Liu X, Callaerts VZ, Evans KL,et al. Chronic infusion of beta-adrenoceptor antagonist and inverse agonists decrease elevated protein kinase a activity in transgenic mice with cardiac-specific overexpression of human beta2-adrenoceptor. J Cardiovasc Pharmacol, 2002,40:448-455.
7Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
